• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Mass Tort News

Mass Tort News

News Articles for Mass Tort Attorneys

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • News
  • LegalCast
  • Live Trials
  • Contact Us
Home / Elmiron / ELMIRON LITIGATION: EMERGING TORTS

ELMIRON LITIGATION: EMERGING TORTS

Categories: Elmiron, Emerging Torts Tags: elmiron, emerging tortsMay 27, 2020 by Rachel Shkolnik Leave a Comment

By Rachel Shkolnik,

Hunter J. Shkolnik

Napoli Shkolnik, PLLC

(May 27, 2020) The nationwide Elmiron eye damage litigation has picked up headlines over the past several months. Elmiron, the brand name for pentosan polysulfate sodium, is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative.[1]  The lawsuit is centralized around the basis that the drug causes an eye disorder called maculopathy and other disorders of the retina that may lead to blindness.  The lawsuits underlying claim is based on failing to properly warn the public about the risk of vision problems.[2] 

Interstitial Cystitis

Elmiron is prescribed to treat interstitial cystitis indicated for the relief of bladder pain or discomfort associated with a bladder condition interstitial cystitis (IC).[3] IC, also known as painful bladder syndrome, is a chronic bladder condition in which individuals are symptomatic of bladder or pelvic pain, urinary frequency, urgency and nocturia. IC is known to affect more woman than men. The American Urological Association (AUA) established IC treatment guidelines separating into six tiers of increasing invasive therapy.[4] Elmiron is not a first-line treatment for IC.

These treatment guidelines begin with the simple lifestyle changes and progress to levels that are more invasive.[5] AUA recommends second-line treatment of IC to incorporate multi-modal pain management approaches including manual therapy and oral therapy options such as pentosyn polysulfate (Elmiron).[6] Elmiron is not the best nor the only option for treating interstitial cystitis. 

[1] https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f0ba651e-3d8a-11df-8fbe-119855d89593&type=display

[2] https://www.drugwatch.com/elmiron/lawsuits/

[3] https://www.orthoelmiron.com/sites/www.orthoelmiron.com/files/021906-150224.pdf

[4] Colaco M, Evans R. Current guidelines in the management of interstitial cystitis. Transl Androl Urol. 2015;4(6):677‐683. doi:10.3978/j.issn.2223-4683.2015.11.03

[5] Colaco M, Evans R. Current guidelines in the management of interstitial cystitis. Transl Androl Urol. 2015;4(6):677‐683. doi:10.3978/j.issn.2223-4683.2015.11.03

The Injury

Elmiron’s associated eye disease is called pigmentary maculopathy. The signature Elmiron eye disease is affecting the central part of the retina. It is caused by retinal toxicity or drug-induced toxicity that damages the retina. Pigmentary maculopathy occurs when the pigment cells alter in the retina causing significant eye damage and vision loss while often changing the eye color.[7] Pigmentary maculopathy symptoms include central visual loss, dark spots in the visual field, prolonged dark adaptation lighting issues, distorted lines, muted colors, and change in eye color.[8] Pigmentary maculopathy may be mild or severe depending on the amount of retinal damage that has occurred.[9]

The macula is the part of the retina that is responsible for producing accurate and highly sensitive vision. Maculopathy, also known as macular degeneration, is a disease related to the central part of the retina, called macula. Maculopathy is characterized by a progressive loss of central vision, usually bilateral, that greatly impairs vision functions. There are several types of maculopathy. Not all maculopathy’s are caused by retinal toxicity.

People who suffer from eye conditions are being misdiagnosed because their symptoms are similar to macular degeneration or even macular pattern dystrophy. Age-related conditions like macular degeneration don’t appear until around age 60. Macular pattern dystrophy stems from genetics.  People may have an Elmiron related injury when they are suffering from eye damage such as: blurred vision, central vision loss, trouble reading, trouble adjusting to dim lighting, prolonged dark adaptation/poor light to dark adaptation, glare, blind spots, metamorphopsia, and blindness.

Dry maculopathy is more frequent compared to wet maculopathy. In 90% of maculopathies are dry ones: the retina gets thinner because vision cells stop working and disappear; for this form, also known as atrophic maculopathy, laser therapy has proven to be ineffective. Nutritive factors transport and waste elimination by the retinal pigmented epithelium (RPE) are slowed down: yellowish intra-retinal deposits (drusen) or pigmented (dystrophy, focal pigment) appear. There is usually a small vision impairment and only in a few cases have been experienced atrophied zones that look like retinal stretch marks and also involve the central part (fovea).

A client might have several conditions resulting in eye sight loss which may or may not be Elmiron related. A person with macular degeneration, which is damage to the macula area in the retina, will suffer from central visual loss, dark spots in the visual field, dark lighting issues, distorted lines, and muted colors. An individual with diabetic retinopathy, which is damage to the blood vessels in the retina, will suffer from blind spots, dark spots and streaks in the visual field, dark lighting issues, and muted colors. An individual with glaucoma, which is damage to the optic nerve in an eye, will suffer from general visual loss, glare and halos in the visual field, dark lighting issues, and redness in the eye. An person with cataracts, which is clouding of the lens of the eye, will suffer from general visual loss, halo and glare in the visual field, dark lighting issues, and whitening in the pupil.

Several eye diseases have similar symptoms to Elmiron induced injuries. Thus, it is vital to obtain fundus and OTC imagining to detect diseased regions and/or atrophy in areas of the retina. Fundus imagery involves photographing the interior surface of the eye to record color images of the condition of the interior surface of the eye, in order to document the presence of disorders and monitor their change over time.  The retina is imaged to document conditions such as pigmentation maculopathy, diabetic retinopathy, age related macular degeneration, macular edema and retinal detachment.

[6] Colaco M, Evans R. Current guidelines in the management of interstitial cystitis. Transl Androl Urol. 2015;4(6):677‐683. doi:10.3978/j.issn.2223-4683.2015.11.03

[7] https://www.livescience.com/34781-macular-degeneration-eye-disease.html

[8] https://www.livescience.com/34781-macular-degeneration-eye-disease.html

[9] https://www.livescience.com/34781-macular-degeneration-eye-disease.html

Literature

Numerous studies conducted by doctors from highly respected hospitals and universities have found a possible connection with long term Elmiron use and severe eyes disorders that can lead to blindness. Peer reviewed literature has established a causal connection between Elmiron and pigmentary maculopathy.  Pigmentary maculopathy may render patients with severe central vision loss that is not repairable or operable.  Literature supports not only a dose and duration association, but latency based on load effect due to the deposit of molecules in the RPE within the macula.           

In May 2018, Emory Eye Center conducted a case study of six adult patients who were treating IC with pentosan polysulfate sodium. The doctors began noticing a new eye disease deemed pigmentary maculopathy in patients with long term Elmiron.

In April 2019, the Emory Eye Center did a further case study of ten patients. The doctors reported that over the last four years, patients who did not treat IC with pentosane polysulfide sodium were not experiencing pigmentary maculopathy.

The first clinical population based study came from Kaiser Permanente in 2019. Kaiser Permanente conducted a study based of 4.3 million patients. Patients showed clear evidence of this specific maculopathy, which was believe was associated with PPS exposure. The research was presented at the “AAO 2019”—the annual meeting of the American Academy of Ophthalmology at Moscone Center, San Francisco. The study revealed that eye damage increased with the quantity of Elmiron intake.[10]

[10] https://www.sciencedirect.com/science/article/abs/pii/S0161642020300403

A Harvard case study involved examining a female with a history of eighteen years of Elmiron use at a low dose of 200mg/day. She was initially presented with symptoms that included blurry vision, difficulty seeing at night, and pigmentary changes in the retina. Two years into the study she returned with more extensive eye damage consistent with pigmentary maculopathy. Harvard doctors concluded that long term Elmiron use results in progression of the disease even after cessation of Elmiron.

Furthermore, animal studies confirm that there is detrimental retinal effects found in mice as a result of pentosan polysulfate administration.

Label: No Warnings!

Since the original report, there have been more than a dozen papers published in the medical literature regarding the atypical maculopathy associated with Elmiron use. Despite all the reports, the label and prescribing information that accompany Elmiron when prescribed to patients contains the following: “Warnings: None.” Elmiron provides no education about potential vision changes nor instruction to have annual eye exams despite the fact that the label has been changed at least four times.

The Elmiron label has been updated several times, but at no time has it contained any information about visual loss, including pigmentary maculopathy, in any section of the label. The drug makers did not do anything to warm the eye damage risks associated with Elmiron- no voluntary recall, no warning label added to the box, not even an announcement to conduct further investigation.  

In October 2019, Health Canada announced pigmentary maculopathy would be added to the “warnings and precautions,” “post – market adverse drug reactions” and “consumer information” sections of the Canadian monograph. However, the United States label still did not change the label. 

Client demographics

The studies suggested the client demographics involve mostly woman between the ages of thirty-seven and seventy-nine years.[11] Elmiron intake lasts as little as three years and as long as twenty-two years.[12] Common presenting symptoms include: blurred vision, prolonged dark adaptation, and metamorphopsia (which is a type of distorted vision in which a grid of straight lines appears wavy and parts of the grid may appear blank).[13] The visual symptoms last from one to nine years. The visual acuity, which is an ability to discern the shapes and details of the things, ranged from 20/20 to 20/300 in the right eye, and ranged from 20/15 to 20/400 in the left eye.[14]

[11] Davis NF, Brady CM, Creagh T. Interstitial cystitis/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options. Eur J Obstet Gynecol Reprod Med. 2014;175(4):30-37; Vora R, Patel A, Melles RS. Maculopathy associated with pentosan polysulfate therapy: the KPNC experience. Paper presented at: AAO Retina Subspecialty Day; October 12-13, 2019; San Francisco, CA.

[12] Davis NF, Brady CM, Creagh T. Interstitial cystitis/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options. Eur J Obstet Gynecol Reprod Med. 2014;175(4):30-37; Vora R, Patel A, Melles RS. Maculopathy associated with pentosan polysulfate therapy: the KPNC experience. Paper presented at: AAO Retina Subspecialty Day; October 12-13, 2019; San Francisco, CA.

Who is responsible?

As indicated on the label, Elmiron® is a Registered Trademark of Teva Branded Pharmaceutical Products R&D, Inc. under license to Janssen Pharmaceuticals, Inc. On September 26, 1996, the U.S. Food and Drug Administration (FDA) approved Elmiron. From approximately August 2002 until August 2004, Janssen Research & Development LLC  held the NDA for Elmiron. From July 2004 until August 2008, Janssen Pharma, Ortho-Mcneil Pharmaceuticals, INC. held the NDA for Elmiron. Since August 2008, Janssen Pharmaceuticals, INC., is the current U.S. Food and Drug Administration (FDA) New Drug Application (NDA) who now manufactures and distributes Elmiron.

Makers of generic drugs cannot be sued for not warning patients of the drugs’ dangerous side effects. However, this issue is not present in the Elmiron litigation, because there is no therapeutically equivalent version of Elmiron available in the United States. The litigation is only involves brand named drugs.

Pending lawsuits

There are multiple Elmiron suits pending in court. On March 26, 2020, the first lawsuit was brought against Teva Branded Pharmaceutical Products R&D, Teva Pharmaceuticals USA, Inc., Janssen Pharmaceuticals, Inc, and Johnson & Johnson, Inc. in the United States District Court for the District of Connecticut. The suit alleges three counts under the Connecticut Products Liability Act.

Shortly thereafter a lawsuit was brought against Janssen Pharmaceuticals, INC., f/k/a Ortho-McNeil-Janssen Pharmaceuticals, Inc., f/k/a Janssen Pharmaceutica Inc.; Ortho-Mcneil Pharmaceuticals, Inc.; Janssen Research & Development LLC f/k/a Johnson & Johnson Research & Development, L.L.C.; Janssen Ortho LLC; and Johnson & Johnson in the Middle District of Florida with six counts. As of now, there is no multi district litigation involving Elmiron but one would expect a filing for such will be coming in the near future.

[13] Davis NF, Brady CM, Creagh T. Interstitial cystitis/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options. Eur J Obstet Gynecol Reprod Med. 2014;175(4):30-37; Vora R, Patel A, Melles RS. Maculopathy associated with pentosan polysulfate therapy: the KPNC experience. Paper presented at: AAO Retina Subspecialty Day; October 12-13, 2019; San Francisco, CA.

[14] Davis NF, Brady CM, Creagh T. Interstitial cystitis/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options. Eur J Obstet Gynecol Reprod Med. 2014;175(4):30-37; Vora R, Patel A, Melles RS. Maculopathy associated with pentosan polysulfate therapy: the KPNC experience. Paper presented at: AAO Retina Subspecialty Day; October 12-13, 2019; San Francisco, CA.

For additional Elmiron information from Napoli Shkolnik, PLLC  see: https://www.napolilaw.com/practice-areas/pharmaceutical-litigation/national-elmiron-eye-disease-lawyers/

Case Criteria

A typical Elmiron claim involves woman, between the ages of thirty to sixty years, ingested Elmiron for at least one year, the Elmiron dosage is at least hundred mg, and suffers from one of the qualifying injuries. The qualifying injuries include: pigmentation maculopathy, pigmentation macular degeneration, pigmentation maculitis, retinal maculopathy or dry macular degeneration. A person may have a viable claim if they have at least four years of Elmiron use with contemporaneous qualifying symptoms such as blurred vision, central vision loss, or prolonged light adaption. 

Although not common, men might have a viable claim if they fall under the criteria. There have been several FDA adverse events reports by men would fall under the case criteria.

Lastly, as in all drug related product liability cases it is important to consider alternative causation issues. Lawyers should keep an eye out for clients with severe kidney disease; liver disease; tamoxifen use; and pre-existing retinal disease as these may affect the viability of claims. Moreover, with the current Covid 19 pandemic and the political debate surrounding the use of Hydroxychloroquine as an off-label treatment for the virus, we expect to see increasing numbers of macular degeneration cases unrelated to Elmiron use and these clients should be screened closely.



About the author: https://www.napolilaw.com/napoli-attorney/rachel-l-shkolnik/

Rachel Shkolnik

(212) 397-1000 Ext. 1050 | [email protected]
360 Lexington Avenue, Eleventh Floor, New York, NY 10017

vCard-R. Shkolnik


Co-author: https://www.napolilaw.com/napoli-attorney/hunter-shkolnik/

Hunter J.  Shkolnik

360 Lexington Avenue, Eleventh Floor, New York, NY 10017

For additional Elmiron information from Napoli Shkolnik, PLLC  see: https://www.napolilaw.com/practice-areas/pharmaceutical-litigation/national-elmiron-eye-disease-lawyers/

Rachel Shkolnik
Rachel Shkolnik

Ms. Shkolnik is an associate with the firm’s Product Liability, Pharmaceutical Department. Prior to joining the Pharmaceutical Department, she focused on premise liability, products liability, labor law, intentional torts as well as civil suits involving victims of sexual assault and/or battery.

www.napolilaw.com/
Share on Facebook Share
Share on TwitterTweet
Share on LinkedIn Share
Send email Mail

Categories: Elmiron, Emerging Torts Tags: elmiron, emerging torts

Reader Interactions

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

Search

E-mail Newsletter

Sign up to receive weekly updates on the latest in Mass Tort News.

Recent Episodes

Jennifer Hoekstra and the Aylstock Witkin trial teamed the charge in more MDL Bellwether trials to verdict in the last 18 months than any prior MDL Bellwether trial track in history, showing how to fast track a trial docket and win again and again. Jennifer has been involved in direct outcomes of Bellwether trials and settlements in excess of 11 billion dollars in MDL. These dockets include leadership roles in the Proton Pump Inhibitor, Genetically Modified Rice, as well as the Actos and DePuy Pinnacle Hip Implant. She has been active in complex litigation since 2007 and shows no sign of slowing down in 2022. We look forward to watching Jennifer maintain her leadership role in the 3M Earplug mediation and settlement negations.
Leading the 3M Earplugs Bellwether Trial Victory Parade!
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LjZYdnZsek4teDVR
Diandra “Fu” Debrosse Zimmermann is managing partner of DiCello Levitt’s Birmingham office, co-managing partner of the Washington, D.C. office, and co-chair of the firm’s Mass Tort division. Fu is also a member of the firm’s Public Client, Environmental, Personal Injury, Civil Rights, and Trial practice groups.
 
Widely known for her passionate and relentless client advocacy, she represents individuals and public entities that have been injured by wrongful conduct, whether from defective medical devices or drugs, environmental contamination, corporate misconduct, or civil rights abuse. She is nationally recognized as a powerhouse in mass torts, class actions, products liability, discrimination, and sexual assault claims, and has recovered hundreds of millions of dollars in client damages. 
 
On May 27, 2022 Fu made history, becoming the first black woman ever appointed plaintiffs’ Co-Lead Counsel in a multidistrict litigation. She was appointed to the role in the massive products liability MDL, In Re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation, against two of the world’s largest manufacturers of infant formula, Abbott Laboratories (NYSE: ABT) and Mead Johnson. Comprised of more than 60 state and federal lawsuits filed across the U.S., the case stems from allegations against the manufacturers of infant formulas Similac (Abbott) and Enfamil (Mead) by parents of premature infants who were fed with that formula and developed the deadly neonatal condition, necrotizing enterocolitis (NEC). 
 
Fu currently represents individuals exposed to Paraquat, an herbicide thought to cause Parkinson’s disease. She also represents victims of civil rights violations, defective products, and other wrongful conduct. Before joining DiCello Levitt, Fu represented dozens of cities and counties in Alabama, Georgia, and Mississippi against opioid manufacturers and distributors. She has also recovered more than $30 million in damages for victims of catastrophic personal injury, product liability, employment discrimination, and civil sexual assault claims. 
 
Earlier this year, in February 2022, Fu announced that she along with Ben Crump co-founded Shades of Mass, an organization aimed at combatting the lack of diverse attorney leadership in lawsuits that disproportionately impact communities of color. Through collaboration, shared resources, education and networking opportunities, and pressure on our profession, Shades of Mass aims to rectify this inequity and achieve the diversity missing in mass tort and complex litigation case leadership. Learn more about Shades of Mass, its mission, its board members, and its board members here: https://www.law.com/2022/02/28/new-gr.... The organization will be hosting a conference in October 2023 in Atlanta. Visit the Shades of Mass website: http://www.shadesofmass.org/, to learn more. 
 
She is well-known for her relentless and compassionate client advocacy which is only matched by her passion to make this world a better place for the generations to come. Fu has extensive experience handling complex litigation, including pharmaceutical, medical device, environmental contamination, and civil rights matters. And she has earned quite a few accolades for her work, including Top 40 Under 40 attorneys (National Trial Lawyers), Top 10 Under 40 attorney for the State of Alabama (National Academy of Personal Injury Attorneys, Inc.), The National Trial Lawyers: Top 100, one of America’s Top 100 High Stakes Litigators®, and selected as a Top Woman Attorney (B-Metro magazine). 
 
Read more about Fu here: https://dicellolevitt.com/attorney/di.... 


Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass...
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews...
Fu Zimmermann Sound Bite Building a Legacy Through Leadership
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LnJyT01tMTRpNENj
Richard “Rick” Meadow is the National Mass Tort Leader as well as the Director of Business Development for The Lanier Law Firm. His responsibilities include overseeing all the firm’s pharmaceutical mass tort litigation in addition to promoting, recruiting, and maintaining associated outside relationships at a national level. Rick has represented the rights of individuals who have been injured by pharmaceuticals, medical devices, asbestos, medical malpractice, defective products, construction defects, lead poisoning, and motor vehicles, as well as the negligence of premises owners and municipalities for over 30 years. He further has extensive experience in the representation of large national insurance companies as an insurance defense attorney. This experience provides a 360-degree perspective of the practice of tort law in the United States. 
Rick has developed an extensive practice in mass tort and aggregate litigation. He has been nominated and selected to a variety of leadership positions by both his peers and courts across the country. He has served in leadership positions in many cases that have resulted in nationwide settlements. 
Rick has been working with Mark Lanier for over 30 years and is an integral part of the Lanier Trial Academy Master Class. This year’s Lanier Trial Academy 6.0; https://laniertrialacademy.com/home, will take place on June 20-23, 2022 in Houston Texas. The program includes a third day and more content, including non-verbal cues, voir dire, examinations, and openings and closings. Check out the agenda here, and if you haven’t already, register here: https://myportal.force.com/LanierTrialAcademy/s/lt-event?id=a1U3m00000Ov12TEAR&site=a0d1N000006V1VMQA0#/loginReg!  
 
Read more about Rick here: https://www.lanierlawfirm.com/attorneys/richard-d-meadow/. 
 
Remember to subscribe and follow us on social media… 

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Rick Meadow, Everybody Knows Your Name
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LkE1SWV2anhKY0lj
Diandra “Fu” Debrosse Zimmermann is managing partner of DiCello Levitt’s Birmingham office, co-managing partner of the Washington, D.C. office, and co-chair of the firm’s Mass Tort division. Fu is also a member of the firm’s Public Client, Environmental, Personal Injury, Civil Rights, and Trial practice groups.
 
Widely known for her passionate and relentless client advocacy, she represents individuals and public entities that have been injured by wrongful conduct, whether from defective medical devices or drugs, environmental contamination, corporate misconduct, or civil rights abuse. She is nationally recognized as a powerhouse in mass torts, class actions, products liability, discrimination, and sexual assault claims, and has recovered hundreds of millions of dollars in client damages. 
 
On May 27, 2022 Fu made history, becoming the first black woman ever appointed plaintiffs’ Co-Lead Counsel in a multidistrict litigation. She was appointed to the role in the massive products liability MDL, In Re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation, against two of the world’s largest manufacturers of infant formula, Abbott Laboratories (NYSE: ABT) and Mead Johnson. Comprised of more than 60 state and federal lawsuits filed across the U.S., the case stems from allegations against the manufacturers of infant formulas Similac (Abbott) and Enfamil (Mead) by parents of premature infants who were fed with that formula and developed the deadly neonatal condition, necrotizing enterocolitis (NEC). 
 
Fu currently represents individuals exposed to Paraquat, an herbicide thought to cause Parkinson’s disease. She also represents victims of civil rights violations, defective products, and other wrongful conduct. Before joining DiCello Levitt, Fu represented dozens of cities and counties in Alabama, Georgia, and Mississippi against opioid manufacturers and distributors. She has also recovered more than $30 million in damages for victims of catastrophic personal injury, product liability, employment discrimination, and civil sexual assault claims. 
 
Earlier this year, in February 2022, Fu announced that she along with Ben Crump co-founded Shades of Mass, an organization aimed at combatting the lack of diverse attorney leadership in lawsuits that disproportionately impact communities of color. Through collaboration, shared resources, education and networking opportunities, and pressure on our profession, Shades of Mass aims to rectify this inequity and achieve the diversity missing in mass tort and complex litigation case leadership. Learn more about Shades of Mass, its mission, its board members, and its board members here: https://www.law.com/2022/02/28/new-group-to-promote-attorneys-of-color-in-mass-torts/. The organization will be hosting a conference in October 2023 in Atlanta. Visit the Shades of Mass website: http://www.shadesofmass.org/, to learn more. 
 
She is well-known for her relentless and compassionate client advocacy which is only matched by her passion to make this world a better place for the generations to come. Fu has extensive experience handling complex litigation, including pharmaceutical, medical device, environmental contamination, and civil rights matters. And she has earned quite a few accolades for her work, including Top 40 Under 40 attorneys (National Trial Lawyers), Top 10 Under 40 attorney for the State of Alabama (National Academy of Personal Injury Attorneys, Inc.), The National Trial Lawyers: Top 100, one of America’s Top 100 High Stakes Litigators®, and selected as a Top Woman Attorney (B-Metro magazine). 
 
Read more about Fu here: https://dicellolevitt.com/attorney/diandra-fu-debrosse-zimmermann/. 


Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Building a Legacy Through Leadership
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LjMxeC13OVJQcjdB
John Uustal and the Kelly Uustal Law Firm are a complex personal injury firm based in Fort Lauderdale FL, who are actively involved in traumatic and catastrophic injury litigation and Mass Torts as local trial counsel for certain MDL leadership firms. Also, KU is one of the premier tobacco litigation firms in the country, securing hundreds of millions of dollars in verdicts against Big Tobacco. Never afraid to face corporate bad conduct, John Uustal and the Kelly Uustal firm will take the fight directly to the corporate boardrooms.

Check out John Uustal's blog to stay up-to-date on corporate treachery: https://www.johnuustal.com/
888.522.6601
https://www.kulaw.com

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Calling Out Boardroom Misconduct in the Courts and Court of Public Opinion
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3Lk03TENRN0s0X3cw
Today we're joined by Majed Nachawati, founder of the Fears Nachawati firm. Majed is well known as a prominent complex commercial litigator in the mass tort space and a leadership firm in emerging torts. Majed's firm is known for representing both individuals and governmental entities in dockets such as the opioid litigation, PFAS water contamination, and other major mass torts. Today we will be discussing three of the most relevant and prominent dockets in the legal world that impact both the plaintiff and defense bar. 

We engage in direct discussions on the Bayer/ Monsanto US Supreme Court appeal in the Hardeman Roundup verdict, originating in California State Court. Recently the US Solicitor General submitted a brief to the Supreme Court advising that the US Department of Justice and other federal agencies are not in favor of participating in the Monsanto- Hardeman appeal.

We then go into the Johnson & Johnson Talcum Powder MDL and related state court litigation where J&J is using the Texas Two-Step legal process to file bankruptcy, related to their talcum powder liabilities, which are expected to exceed $12 billion. Majed is also a member of the J&J bankruptcy creditor's committee.   

Majed also discusses his lead role in the Texas winter freeze litigation, where the Texas Utility Power Commission and the power grid tragically failed the citizens of Texas and numerous lives were lost, properties were destroyed and damaged. Fears Nachawati was in a leadership role from the outset of the Texas winter freeze litigation, when they filed the first lawsuit within one week of the freeze taking place. The claims in this docket relate to the catastrophic failure of the utility and regulatory entity within the state of Texas to properly ensure the safety of its citizens. Majed clearly states that it is his position in the Texas winter freeze, Monsanto roundup, and the Johnson and Johnson talcum powder litigation to be an assertive representative of firm clients in these dockets to hold the corporate parties accountable for the ongoing and embedded bad conduct, which is clearly evident in the media and now being shown in a court of law.

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Fighting Bad Conduct in America's Boardrooms
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LldJbmlZQ0VkM0Fn
John K. Rabiej served as the Deputy Director of the Bolch Judicial Institute for one year, and as the Director of the Duke Law Center for Judicial Studies for seven years. The Duke Law Center brings together judges, lawyers, researchers, government officials and other parties to advance the study and understanding of the judicial process and generate ideas for how it might be improved. During his time as the Director of the Duke Law Center, Mr. Rabiej studied the impact of technology on the judiciary, including analyzing his concerns that the courts are not keeping pace with the rapid advancement of technology in the culture at large. Prior to joining the Duke Law Center, Mr. Rabiej served as the Executive Director and Director of Judicial Outreach for The Sedona Conference; the Chief of the Rules Committee Support Office; and the American Law Institute. He presently sits on the Chief Justice’s Rules Advisory Commission, North Carolina (term ending December 31, 2023). In this episode of LegalCast, Mr. Rabiej discusses a legal bipartisan review of mass torts, class action, and the ever-expanding e-discovery quagmire that seems to be firmly embedded in complex litigation coming to a peak in 2022.  Will the plaintiffs and defense leadership be able to collaborate to reign in the ever-expanding high cost of litigation? Mr. Rabiej has made a career of working to bring opposing groups together to discuss common interests as a means to increase efficiencies in litigations. And, with millions of dollars at stake, why not at least start the discussions.

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Is Judicial Review On The Horizon?
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LmlkM1ZiUVJMYkdZ
Stephen P New. of Beckley West Virginia is one of the country’s leading opioid litigators, by bringing the fight directly to Opioid Big Pharma's doorstep. Steve and the Opioid Justice Team have been defending and advocating for the rights of the neonatal abstinence syndrome afflicted infants, aka the "NAS Babies." Who are the truly innocent victims of the now decades-old opiate crisis in America.

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Leading the Fight for Opioid Addicted Infants
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LnhNbHdDSGU3ZzZZ
George Haj is a Pulitzer-Prize winning editor who founded Haj Media in 2017. Haj Media is a strategic communications firm focusing on crisis communications, media relations, and litigation support for law firms and corporate clients. Prior to launching his own consulting firm, George spent three decades working in some of the nation’s largest news organizations. He has deep roots in the media industry and connections with reporters and editors in a range of publications across the country. George worked as executive business editor at the Miami Herald and then was a top editor at the Houston Chronicle. He also served as editorial director of ALM Media, where he directed a global newsroom of more than 100 journalists and oversaw iconic brands including The American Lawyer and National Law Journal. He can be reached at george@hajmedia.com. Find him on Twitter: https://twitter.com/georgehaj, LinkedIn: https://www.linkedin.com/in/george-haj-25ba481, and at http://www.hajmedia.com/. 

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Crisis Management & Media Training for Lawyers
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LmhvVDk2Q2MxUnpR
With four decades of experience in legal advertising with a passion for legal marketing, intake, and conversion, Harlan Schillinger has more than earned his title as the Grandfather of Legal Advertising. 

Harlan was the first in the industry to produce and market TV advertising for the legal community. In 1975, along with his partners, Harlan founded the first syndication TV production firm for high-end retailers and Lawyers, creating television commercials that aired throughout North America.

Since the late 1970s, Harlan has worked aggressively, productively, and professionally within the legal advertising space. He has said that: “Creating opportunities and increasing market share for advertising law firms is [his] #1 priority. The value of the case is everything in such a crowded market.” Harlan privately consults with lawyers who not only share his values, but who also share his vision of increasing business, being accountable, and obtaining high-value cases. His approach to intake and conversion rests on complete accountability within that area and he is known to practice what he preaches. Harlan has trademarked within the legal advertising world the two phrases that have become his backbone of philosophy: What You Don't Know, You Don't Know® and Ambassador of First Impressions™.

Since that time, Harlan has worked with more than 130 law firms in almost 100 markets throughout North America. Before joining Network Affiliates in 1985, Harlan was a founding partner and VP of Madison, Muyskens & Jones, a Connecticut-based advertising agency. In April 2016 Harlan retired from Colorado-based Network Affiliates, the nation's first and largest full-service legal advertising agency, where he was the leader of their attorney marketing efforts for over 34 years.

A few years ago, Harlan and two of his partners – Dino Colombo Esq. and Eric Coffman – developed Lead Docket, software for intake and conversion within law firms. Harlan says that Lead Docket helps law firms increase control and management of intake and conversion, allowing the firms to thrive.

Harlan is involved with a number of professional organizations, being a member of the National Trial Lawyers Executive Summit Committee as well as a Senior Editor and Writer for the National Trial Lawyers Magazine. He also has a passion for riding and building custom motorcycles, and is a proud member of the most prestigious motorcycle group in the world: Hamsters USA ® Motorcycle Group.

Learn more about Harlan at http://www.harlanschillinger.com/. 
And to check out the book he recommends – How to Win Friends & Influence People by Dale Carnegie and originally published in 1936 click here: https://www.amazon.com/How-Win-Friends-Influence-People/dp/0671027034. 

Remember to subscribe and follow us on social media…

LinkedIn: https://www.linkedin.com/company/mass-tort-news
Twitter: https://www.twitter.com/masstortnewsorg
Facebook: https://www.facebook.com/masstortnews.org
Prep Like a Pro: Legal Networking Tips & Tricks
YouTube Video VVVuSC1KSll3UzVNWHQwMEgyUndoR3Z3LjJJRW9MWUh1UkZ3
Load More... Subscribe

Popular Tags

current litigationopioid crisisconsumer protectioncovid-19zantacemerging tortspurdue pharmaeventparaquatgeneral news

Footer

Search

Main Navigation

  • Home
  • News
  • LegalCast
  • Live Trials
  • Contact Us

Categories

Events

Trial Lawyers Summit 2022

February 16, 2022 By Mass Tort News

2021 Trial Lawyers Summit Recap

May 11, 2021 By Mark York

2021 TRIAL LAWYERS SUMMIT

May 4, 2021 By Mass Tort News

More Posts from this Category

MASS TORT NEWS

Latest Mass Tort Litigation News

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Copyright © 2022 · Mass Tort News · All Rights Reserved.